Theranib Inc. is a Nova Scotian biotech company pioneering precision first-in-class cancer therapies targeting ALDH1A3, a novel target to inhibit metastasis and therapy resistance in solid tumors including breast, lung, pancreatic, ovarian and brain cancers. Their approach combines novel small molecule drug design with a biomarker assay to identify cancer patients most likely to benefit from our drug, maximizing efficacy, and aiming to improve outcomes and investor returns.